Linsitinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLinsitinib
Drug Alias NameLinsitinibum林西替尼林司替尼OSI-906OSI-906AA +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin receptor inhibitorsInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptorInsulin receptor
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursHashimoto Disease +[30] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesAstellas Pharma IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesSling Therapeutics Inc
Inactive CompaniesDana-Farber Cancer InstituteOhsu Knight Cancer InstituteUniversity Of Oxford +[13] 
Active IndicationsHashimoto DiseaseThyroid DiseasesExophthalmos +[4] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursEndocrine System Diseases +[26] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG